Kiniksa raises 2026 ARCALYST sales guidance, confirms KPL-387 data timing

Kiniksa Pharmaceuticals International reported third quarter 2026 results on October 27, 2026 and raised its full-year outlook for ARCALYST. The company said it now expects 2026 ARCALYST net sales of between $1.045 and $1.050 billion, up from its previous range of between $980 and $995 million.¹

On the pipeline, Kiniksa said it continues to enroll and dose patients in PASTORALE, the pivotal Phase 3 trial of KPL-387 evaluating once monthly subcutaneous dosing, with data expected in the second half of 2027, and a goal of bringing the treatment to patients in the 2028/2029 timeframe.¹ The company is also running a supplemental Phase 2 study evaluating the transition of patients from standard therapies to KPL-387 monotherapy dosing and administration.¹

For KPL-1161, an Fc-modified antibody targeting IL-1R1, Kiniksa said it expects to initiate a Phase 1 first-in-human trial, targeting quarterly subcutaneous dosing, by the end of 2026.¹

On ARCALYST's commercial reach, the company said roughly 23% of an estimated 14,000 annual multiple-recurrence patients were actively on ARCALYST treatment as of the end of the third quarter of 2026,¹ and that more than 5,450 prescribers have written ARCALYST prescriptions for recurrent pericarditis since launch.¹

Quarterly revenue showed the scale of that growth: ARCALYST net product revenue was $286.0 million for the third quarter of 2026.¹ Net income for the quarter was $47.3 million, compared to $18.4 million for the third quarter of 2025.¹

On the balance sheet, Kiniksa said it had $568.8 million of cash, cash equivalents, and short-term investments and no debt as of September 30, 2026,¹ and that it expects its current operating plan to remain cash flow positive on an annual basis.¹